(NE)-N-[2-(imidazol-1-ylmethyl)cyclohexylidene]hydroxylamine | 1243263-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (NE)-N-[2-(imidazol-1-ylmethyl)cyclohexylidene]hydroxylamine
• CAS: 1243263-80-0
• 化学式: C₁₀H₁₅N₃O
• 分子量: 193.249
• InChiKey: YAJDOQSLRRKPHY-ZRDIBKRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (NE)-N-[2-(imidazol-1-ylmethyl)cyclohexylidene]hydroxylamine 、 异氰酸间氰基苯酯 以 二氯甲烷 为溶剂， 生成 (1E)-2-(imidazol-1-ylmethyl)-cyclohexanone O-[(3-cyanophenyl)carbamoyl]oxime
  参考文献：
  名称：

  Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists

  摘要：

  Hit-to-lead optimization of a HTS hit led to new carbamoyloxime derivatives. After identification of an advanced hit (8d) the CYP enzyme inhibitory activity of this class of compounds was successfully eliminated. Systematic exploration of different parts of the advanced hit led us to some promising lead compounds with mGluR5 affinities comparable to that of MPEP. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.075
• 作为产物：
  描述：

  2-imidazol-1-ylmethyl-cyclohexanone 在 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 、 水 为溶剂， 生成 (NZ)-N-[2-(imidazol-1-ylmethyl)cyclohexylidene]hydroxylamine 、 (NE)-N-[2-(imidazol-1-ylmethyl)cyclohexylidene]hydroxylamine
  参考文献：
  名称：

  Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists

  摘要：

  Hit-to-lead optimization of a HTS hit led to new carbamoyloxime derivatives. After identification of an advanced hit (8d) the CYP enzyme inhibitory activity of this class of compounds was successfully eliminated. Systematic exploration of different parts of the advanced hit led us to some promising lead compounds with mGluR5 affinities comparable to that of MPEP. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.075

文献信息

• [EN] MGLUR5 ANTAGONISTIC CARBAMOYL-OXIME DERIVATIVES<br/>[FR] DERIVES DE CARBAMOYLOXIME ANTAGONISTES DE MGLUR5
  申请人：RICHTER GEDEON VEGYESZETU GYAR

  公开号：WO2007072089A1

  公开（公告）日：2007-06-28

  [EN] The present invention relates to new mGluR5 receptor subtype preferring ligands of formula (I): (I) wherein R₁ and R₂ represent independently a substituent selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl and cyano; X is a CHR6 group or O; R₃ represents an alkyl substituent, R₄ and/or R₅ represent hydrogen, R₆ is hydrogen or alkyl, or R₃ and R₄ with the intermediate two carbon atoms together form a cyclohexane or cyclopentane ring and/or R₅ and R₆ together form a bond; Y is an optionally substituted phenyl or heterocyclyl, and/or enantiomers and/or racemates and/or diastereomers and/or geometric isomers and/or salts and/or hydrates and/or solvates thereof, to the process for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of pathological conditions which require the modulation of niGluR5 receptor such as neurological disorders, psychiatric disorders, acute and chronic pain and neuromuscular dysfunctions of the lower urinary tract.
  [FR] La présente invention concerne de nouveaux ligands préférentiels du sous-type de récepteur mGluR5 de formule (I): (I) où R₁ et R₂ représentent indépendamment un substituant choisi parmi l'hydrogène, un halogène, un alkyle, un alcoxy, un halogénoalkyle et un cyano ; X est un groupe CHR6 ou O ; R₃ représente un substituant alkyle, R₄ et/ou R₅ représentent un hydrogène, R₆ est un hydrogène ou un alkyle, ou R₃ et R₄ avec les deux atomes de carbone intermédiaires forment conjointement un cycle cyclohexane ou cyclopentane et/ou R₅ et R₆ forment conjointement une liaison ; Y est un phényle ou hétérocyclyle facultativement substitué, et/ou des énantiomères et/ou des racémates et/ou des diastéréo-isomères et/ou des isomères géométriques et/ou des sels et/ou des hydrates et/ou des solvates de ceux-ci, le procédé pour préparer ceux-ci, des compositions pharmaceutiques contenant ceux-ci et leur utilisation en thérapie et/ou prévention d'états pathologiques qui requièrent la modulation de récepteur de mGluR5 tels que des troubles neurologiques, des troubles psychiatriques, la douleur aiguë et chronique et des dysfonctionnements neuromusculaires du tractus urinaire inférieur.
• Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists
  作者：János Galambos、Gábor Wágner、Katalin Nógrádi、Attila Bielik、László Molnár、Amrita Bobok、Attila Horváth、Béla Kiss、Sándor Kolok、József Nagy、Dalma Kurkó、Mónika L. Bakk、Mónika Vastag、Katalin Sághy、István Gyertyán、Krisztina Gál、István Greiner、Zsolt Szombathelyi、György M. Keserű、György Domány

  DOI：10.1016/j.bmcl.2010.06.075

  日期：2010.8

  Hit-to-lead optimization of a HTS hit led to new carbamoyloxime derivatives. After identification of an advanced hit (8d) the CYP enzyme inhibitory activity of this class of compounds was successfully eliminated. Systematic exploration of different parts of the advanced hit led us to some promising lead compounds with mGluR5 affinities comparable to that of MPEP. (C) 2010 Elsevier Ltd. All rights reserved.